Allogene Therapeutics, Inc. (NASDAQ:ALLO – Get Free Report) Director Franz B. Humer sold 11,200 shares of the company’s stock in a transaction that occurred on Thursday, May 30th. The stock was sold at an average price of $2.34, for a total value of $26,208.00. Following the completion of the sale, the director now owns 255,253 […]
Allogene Therapeutics, Inc. (NASDAQ:ALLO – Get Free Report) has been assigned an average recommendation of “Moderate Buy” from the ten ratings firms that are currently covering the stock, Marketbeat reports. Three equities research analysts have rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 12-month […]
Piper Sandler initiated coverage on shares of Allogene Therapeutics (NASDAQ:ALLO – Free Report) in a report published on Friday, Marketbeat reports. The brokerage issued an overweight rating and a $11.00 target price on the stock. ALLO has been the subject of several other research reports. Royal Bank of Canada reissued an outperform rating and issued […]
Truist Financial reiterated their buy rating on shares of Allogene Therapeutics (NASDAQ:ALLO – Free Report) in a research note issued to investors on Wednesday, Benzinga reports. They currently have a $17.00 price target on the stock. A number of other analysts also recently weighed in on ALLO. Royal Bank of Canada reiterated an outperform rating […]
Allogene Therapeutics, Inc. (NASDAQ:ALLO – Free Report) – Research analysts at William Blair decreased their Q2 2024 EPS estimates for shares of Allogene Therapeutics in a research report issued on Tuesday, May 14th. William Blair analyst S. Corwin now expects that the company will post earnings per share of ($0.39) for the quarter, down from […]